Financial insights of CLNN

MyFinsight

For the quarter ending 2026-03-31, CLNN made $15K in revenue. -$8,047K in net income. Net profit margin of -53646.67%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	15	77	15	27
Cost of revenue	0	23	0	0
Research and development	329	5,503	3,513	3,514
General and administrative	1,747	2,046	2,150	2,377
Total operating expenses	2,076	7,572	5,663	5,891
Loss from operations	-2,061	-7,495	-5,648	-5,864
Interest income	47	40	40	62
Interest expense	791	746	649	679
Loss on extinguishment of notes payable	-	0*	-	-
Issuance costs for common stock warrant liabilities	393	0*	-	-
Loss on initial issuance of equity	-4,582	0*	-	-
Change in fair value of common stock warrant liabilities	1,060	789	1,728	515
Change in fair value of derivative liabilities	713	-274	-797	-439
Change in fair value of clene nanomedicine contingent earn-out liability	-	0*	0	0
Change in fair value of initial stockholders contingent earn-out liability	-	0*	0	0
Research and development tax credits and unrestricted grants	36	38	5	16
Other expense, net	-	0*	-	-
Total other income (expense), net	-6,030	-1,731	-3,129	-1,555
Net loss before income taxes	-8,091	-9,226	-8,777	-7,419
Income tax expense	0	0	0	0
Net loss	-8,091	-9,226	-8,777	-7,419
Unrealized loss on available-for-sale securities	-	0	0	0
Foreign currency translation adjustments	44	22	1	63
Total other comprehensive income	44	22	1	63
Comprehensive loss	-8,047	-9,204	-8,776	-7,356

Basic EPS	-0.69	-0.852	-0.85	-0.78
Basic Average Shares	11,644,214	10,802,689	10,284,674	9,523,592

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.